T Zang1, F Sun, Y Li. 1. Department of Urologic Surgery, Beijing Military General Hospital, Beijing 100700, China.
Abstract
OBJECTIVE: To investigate the expression of COX-2 in and benign prostatic hyperplasia and prostate cancer and its clinical implications. METHODS: Forty-two patients with and benign prostatic hyperplasia and 16 with prostate cancer were studied by immunohischemistry and western blot. RESULTS: Immunohischemiscal study showed positive results in 15 of the 16 patients and 11 of the 42 patients. Western blot showed that the expression of COX-2 was higher in prostate cancer than in and benign prostatic hyperplasia tissues(P < 0.01). CONCLUSION: Overexpression of COX-2 in prostate cancer may be related to the staging of prostate cancer.
OBJECTIVE: To investigate the expression of COX-2 in and benign prostatic hyperplasia and prostate cancer and its clinical implications. METHODS: Forty-two patients with and benign prostatic hyperplasia and 16 with prostate cancer were studied by immunohischemistry and western blot. RESULTS: Immunohischemiscal study showed positive results in 15 of the 16 patients and 11 of the 42 patients. Western blot showed that the expression of COX-2 was higher in prostate cancer than in and benign prostatic hyperplasia tissues(P < 0.01). CONCLUSION: Overexpression of COX-2 in prostate cancer may be related to the staging of prostate cancer.
Authors: Panagiotis J Vlachostergios; Foteini Karasavvidou; Anna Patrikidou; Ioannis A Voutsadakis; Grigorios Kakkas; George Moutzouris; Elias Zintzaras; Danai D Daliani; Michael D Melekos; Christos N Papandreou Journal: Pathol Oncol Res Date: 2011-07-23 Impact factor: 3.201